Dynamic Trends Seen in Clinical Laboratory Services
By LabMedica International staff writers Posted on 20 Jan 2014 |
The constant pressure to reduce healthcare spending is shifting healthcare utilization in favor of the laboratory. Approximately 80% of physicians' diagnoses are a result of laboratory tests, and a number of these tests are sent to clinical lab service providers. Kalorama Information (New York, NY, USA) has published a new report based on a research study of the market for clinical lab services.
A trend towards preventive and risk factor testing is noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking advantage of testing for early detection and disease prevention. Key market data provided includes hospital, physician, and independent lab statistics, major tests performed by clinical lab companies, disease incidence, trends driving lab business, and a market forecast to 2018. The geographic breakout of the clinical lab services market includes the US, Europe and Asia, and specific breakouts for Germany, Japan, China, India, and Brazil.
Some of the other issues and trends explored in the report include US demographics, types of specialty tests, growing competition, increasing life expectancy, the growing incidence of disease, and developments in personalized medicine.
A competitive analysis of leading clinical laboratory providers includes Quest Diagnostics, Inc., Laboratory Corporation of America, Genomic Health, Genoptix, Genzyme Corporation, DaVita, Clarient, Spectra Labs, and Bio-Reference Labs.
The most important part of Kalorama's efforts is its analysis of company activities and their significance in the marketplace. Historical data is provided for the years 2008–2012, with forecast data provided for 2013 through 2017. A competitive analysis is provided for the year 2013. The predicted market analysis for 2013–2017 was largely based on demographic trends, new developments, company performance trends, mergers and acquisitions, and national expansion.
Related Links:
Kalorama Information
A trend towards preventive and risk factor testing is noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking advantage of testing for early detection and disease prevention. Key market data provided includes hospital, physician, and independent lab statistics, major tests performed by clinical lab companies, disease incidence, trends driving lab business, and a market forecast to 2018. The geographic breakout of the clinical lab services market includes the US, Europe and Asia, and specific breakouts for Germany, Japan, China, India, and Brazil.
Some of the other issues and trends explored in the report include US demographics, types of specialty tests, growing competition, increasing life expectancy, the growing incidence of disease, and developments in personalized medicine.
A competitive analysis of leading clinical laboratory providers includes Quest Diagnostics, Inc., Laboratory Corporation of America, Genomic Health, Genoptix, Genzyme Corporation, DaVita, Clarient, Spectra Labs, and Bio-Reference Labs.
The most important part of Kalorama's efforts is its analysis of company activities and their significance in the marketplace. Historical data is provided for the years 2008–2012, with forecast data provided for 2013 through 2017. A competitive analysis is provided for the year 2013. The predicted market analysis for 2013–2017 was largely based on demographic trends, new developments, company performance trends, mergers and acquisitions, and national expansion.
Related Links:
Kalorama Information
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance